GenCRISPR™ Cas9 v1.2 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus localization signal (nucleoplasmin NLS) at C-terminal. It has been reported that BPNLS and nucleoplasmin NLS are able to improve the gene editing efficiency.
GenCRISPR™ Cas9 v1.2 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus localization signal (nucleoplasmin NLS) at C-terminal. It has been reported that BPNLS and nucleoplasmin NLS are able to improve the gene editing efficiency.
Shipping & Handling
Shipped In
DRY ICE
Safety & Storage
Storage Temperature
-20°C
Safety Statement
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Regulatory & Compliance
Specifications
CLASS
Proteins, Enzymes
COUNTRY OF ORIGIN
China
*USAGE / SAFETY STATEMENT
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
PURITY
≥ 90%
as analyzed by SDS-PAGE<br>
SOURCE
Recombinant
Cas9 with a BPNLS at N-terminal and a nucleoplasmin NLS at C-terminal expressed
by <i>E.coli</i><b> </b><br>
CONCENTRATION
4 mg/ml<br>
PHYSICAL FORM
Liquid
SIZE
500μg
APPLICATION.1
gRNA-dependent double-stranded DNA cleavage<br>
Questions & Answers (0)
Citations (0)
Shipping & Handling
Shipped In
DRY ICE
Safety & Storage
Storage Temperature
-20°C
Safety Statement
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.